N-methylpiperidine-4-carboxamide → HCID 44545387, compound

HRID 2093401Notes

Reaction equation

HRID 2093401 reaction equation
C(OC([NH:8][C:9]1[N:14]=[CH:13][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][C:25]([OH:27])=O)=[C:17]([N:28]3[CH2:33][CH2:32][O:31][CH2:30][CH2:29]3)[N:16]=2)=[CH:11][N:10]=1)=O)(C)(C)C.[CH3:34][NH:35][C:36]([CH:38]1[CH2:43][CH2:42][NH:41][CH2:40][CH2:39]1)=[O:37]>>[NH2:8][C:9]1[N:10]=[CH:11][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][C:25]([N:41]3[CH2:42][CH2:43][CH:38]([C:36]([NH:35][CH3:34])=[O:37])[CH2:39][CH2:40]3)=[O:27])=[C:17]([N:28]3[CH2:29][CH2:30][O:31][CH2:32][CH2:33]3)[N:16]=2)=[CH:13][N:14]=1

Participants

3

Reactant 2

HCID 2760460N-methylpiperidine-4-carboxamideHCID 58015218HCID 58015218, compound

Product 1

HCID 44545387HCID 44545387, compound

Procedure

2-(2-(2-(Tert-butoxycarbonylamino)pyrimidin-5-yl)-6-morpholino-9H-purin-9-yl)acetic acid (35 mg) was reacted with N-methylpiperidine-4-carboxamide via General Procedure F followed by Boc deprotection via General Procedure E and purified via reverse phase HPLC to give 10.3 mg 122 as a white solid. MS (Q1) 481.2 (M)+.

Workup

  1. custompurified via reverse phase HPLC

Sources & evidence

ORD record
ord-453a08a1857845cba03d5bb5700965d3
Source dataset
uspto-grants-2013_05
Patent number
US08445487B2

Reaction notes

Loading…